Intensified 14-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A systematic review and meta-analysis of randomized controlled trials

被引：0
|
作者：
Sandoval-Sus, J. D. [1 ]
Dalia, S. [2 ]
Mhaskar, R. S. [3 ]
Chavez, J. C. [4 ]
Ausekar, A. [5 ]
Purnapatre, K. [5 ]
Scheiber, J. [5 ]
Sokol, L. [4 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Pembroke Pines, FL USA
[2] Mercy Clin, Oncol & Hematol, Joplin, MO USA
[3] Univ S Florida, Internal Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
[5] Personome, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1011PD
引用
收藏
页数：2
相关论文
共 24 条
  • [1] Intensified 14-Day Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (RCHOP14) Compared to R-CHOP (RCHOP21) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT)
    Sus, Jose Sandoval
    Dalia, Samir
    Mhaskar, Rahul
    Auseker, Aniket
    Chavez, Julio
    Sokol, Lubomir
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S276 - S277
  • [2] How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials
    Stergios Intzes
    Marianthi Symeonidou
    Konstantinos Zagoridis
    Aikaterini Pentidou
    Zoi Bezirgianidou
    Menelaos Papoutselis
    Christina Misidou
    Christoforos Roumpakis
    Athina Spanoudaki
    Konstantinos Liapis
    Emmanouil Spanoudakis
    [J]. Annals of Hematology, 2024, 103 : 1623 - 1633
  • [3] How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials
    Intzes, Stergios
    Symeonidou, Marianthi
    Zagoridis, Konstantinos
    Pentidou, Aikaterini
    Bezirgianidou, Zoi
    Papoutselis, Menelaos
    Misidou, Christina
    Roumpakis, Christoforos
    Spanoudaki, Athina
    Liapis, Konstantinos
    Spanoudakis, Emmanouil
    [J]. ANNALS OF HEMATOLOGY, 2024, 103 (03) : 947 - 956
  • [4] RCHOP-21 Vs. RCHOP-14 for the Treatment of Newly Diagnosed Diffuse Large B Cell Lymphoma: A Prospective Randomized Phase III Clinical Trial from Cswog
    Lin, Tongyu
    Huang, He
    Li, Xueying
    Guo, Chengcheng
    Hong, Huangming
    Fu, Xiaohong
    Lin, Xiaoting
    Fang, Xiaojie
    Wang, Zhao
    Xia, Zhongjun
    [J]. BLOOD, 2015, 126 (23)
  • [5] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
    Cunningham, David
    Hawkes, Eliza A.
    Jack, Andrew
    Qian, Wendi
    Smith, Paul
    Mouncey, Paul
    Pocock, Christopher
    Ardeshna, Kirit M.
    Radford, John A.
    McMillan, Andrew
    Davies, John
    Turner, Deborah
    Kruger, Anton
    Johnson, Peter
    Gambell, Joanna
    Linch, David
    [J]. LANCET, 2013, 381 (9880): : 1817 - 1826
  • [6] A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
    Younes, Anas
    Sehn, Laurie H.
    Johnson, Peter
    Zinzani, Pier Luigi
    Hong, Xiaonan
    Zhu, Jun
    Samoilova, Olga
    Suh, Cheolwon
    Matsumura, Itaru
    Lopez-Hernandez, Andres
    Duehrsen, Ulrich
    Thieblemont, Catherine
    Carey, Jodi
    Liu, Grace
    Shreeve, S. Martin
    Sun, Steven
    Vermeulen, Jessica
    Staudt, Louis M.
    Wilson, Wyndham H.
    [J]. BLOOD, 2018, 132
  • [7] CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituxamib) in first-line therapy of diffuse large B cell lymphoma (DLBCL): An interim analysis
    Herbrecht, Raoul
    Couban, Stephen
    Weissinger, Florian
    Gorbatchevsky, Igor
    van der Jagt, Richard H.
    [J]. BLOOD, 2007, 110 (11) : 1009A - 1010A
  • [8] RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis
    He, Yue
    Tao, Wenqiang
    Ji, Dexiang
    Lu, Wei
    Xiong, Yu
    Chen, Guoan
    [J]. TRANSLATIONAL CANCER RESEARCH, 2021, 10 (05) : 2044 - 2054
  • [9] Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study.
    Delarue, R.
    Mounier, N.
    Haioun, C.
    Coiffier, B.
    Gisselbrecht, C.
    Ghesquieres, H.
    Lederlin, P.
    Blanc, M.
    Recher, C.
    Hermine, O.
    Reyes, F.
    Tilly, H.
    Bosly, A.
    [J]. BLOOD, 2006, 108 (11) : 689A - 689A
  • [10] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
    Sawalha, Yazeed
    Welkie, Rina Li
    Krivenko, Anna
    Hess, Brian
    Sigmund, Audrey M.
    Voorhees, Timothy
    Hanel, Walter
    Bond, David A.
    Reneau, John C.
    Epperla, Narendranath
    Alinari, Lapo
    Brammer, Jonathan E.
    Christian, Beth
    Baiocchi, Robert
    Maddocks, Kami J.
    [J]. BLOOD, 2023, 142
123